Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)
· seekingalpha.com
Gilead (GILD) Q2 2026 earnings call recap: raised HIV/PrEP outlook, Yeztugo momentum, Veklury reset, and deal-driven EPS hit.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...